Literature DB >> 15732511

Delayed endolymphatic hydrops as a clinical entity.

Tamio Kamei1.   

Abstract

Delayed endolymphatic hydrops (DEH) is a clinical entity that can be differentiated from Ménière's disease and is typically observed in patients who have been suffering from longstanding unilateral profound inner-ear hearing loss. DEH probably is caused by delayed atrophy or fibrous obliteration of the endolymphatic resorptive system of the membranous labyrinth. The time that elapses between the occurrence of hearing loss and the onset of DEH can range from 1 to 74 years. The most common cause of hearing loss preceding DEH is juvenile-onset unilateral profound deafness (early childhood unilateral profound sensorineural hearing loss of unknown etiology), followed by labyrinthitis from various causes and physical and acoustic traumas to the inner ear. Two types of DEH exist: the ipsilateral type, in which the ear with profound hearing loss suffers progressive endolymphatic hydrops, and the contralateral type, in which the formation of progressive endolymphatic hydrops takes place in the ear opposite to the previously deafened ear. The incidence of the ipsilateral type is higher than that of the contralateral type, and the contralateral type is more common in older patients. When recurrent episodic vertigo cannot be remedied through conservative treatment, labyrinthectomy and vestibular neurectomy on the deaf ear are curative for ipsilateral DEH. However, no such surgical treatment is available for the contralateral type.

Entities:  

Mesh:

Year:  2004        PMID: 15732511

Source DB:  PubMed          Journal:  Int Tinnitus J        ISSN: 0946-5448


  17 in total

Review 1.  [Diagnostic criteria for Menière's disease according to the Classification Committee of the Bárány Society].

Authors:  J A Lopez-Escamez; J Carey; W-H Chung; J A Goebel; M Magnusson; M Mandalà; D E Newman-Toker; M Strupp; M Suzuki; F Trabalzini; A Bisdorff
Journal:  HNO       Date:  2017-11       Impact factor: 1.284

2.  Surgical indication in Menière's disease therapy: clinical and epidemiological aspects.

Authors:  Roberto Albera; Andrea Canale; Fiorella Parandero; Alessandro Ducati; Michele Lanotte
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-01-19       Impact factor: 2.503

3.  Otolithic membrane damage in patients with endolymphatic hydrops and drop attacks.

Authors:  Audrey P Calzada; Ivan A Lopez; Gail Ishiyama; Akira Ishiyama
Journal:  Otol Neurotol       Date:  2012-12       Impact factor: 2.311

Review 4.  Vertigo and autoimmunity.

Authors:  Roberto Bovo; Andrea Ciorba; Alessandro Martini
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-10-16       Impact factor: 2.503

5.  Clinical features of delayed endolymphatic hydrops and intralabyrinthine schwannoma : An imaging-confirmed comparative case series. English version.

Authors:  C Jerin; E Krause; B Ertl-Wagner; R Gürkov
Journal:  HNO       Date:  2017-01       Impact factor: 1.284

6.  [Clinical features of delayed endolymphatic hydrops and intralabyrinthine schwannoma : An imaging-confirmed comparative case series. German version].

Authors:  C Jerin; E Krause; B Ertl-Wagner; R Gürkov
Journal:  HNO       Date:  2016-12       Impact factor: 1.284

7.  Vibration-induced nystagmus in patients with unilateral peripheral vestibular disorders.

Authors:  Sujiang Xie; Jia Guo; Ziming Wu; Dongchang Qiang; Jing Huang; Yingjuan Zheng; Qin Yao; Shan Chen; Dawei Tian
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2013-03-16

Review 8.  [Menière's disease : evidence and controversies].

Authors:  M Westhofen
Journal:  HNO       Date:  2009-05       Impact factor: 1.284

9.  Intratympanic steroids injection is effective for the treatment of drop attacks with Ménière's disease and delayed endolymphatic hydrops: A retrospective study.

Authors:  Bo Liu; Yangming Leng; Renhong Zhou; Jingjing Liu; Dongdong Liu; Su-Lin Zhang; Wei-Jia Kong
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

10.  Repeated Audiometry After Bacterial Meningitis: Consequences for Future Management.

Authors:  Marian B A Rodenburg-Vlot; Liesbet Ruytjens; Rianne Oostenbrink; Marc P van der Schroeff
Journal:  Otol Neurotol       Date:  2018-06       Impact factor: 2.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.